
New 2026 cholesterol guidelines from major cardiology groups simplify and personalize prevention by lowering LDL targets, recommending earlier screening, and adding routine lipoprotein(a) (Lp(a)) testing. The changes are intended to identify higher-risk people at younger ages and expand who may be advised to start cholesterol-lowering therapy. This update aligns with other reporting urging earlier treatment for millions and with calls to formally include Lp(a) in standard risk assessments.
Click a connection line between nodes to view confidence and evidence.